Compare EARN & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | SENS |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Machinery/Components |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 301.2M |
| IPO Year | 2012 | 2014 |
| Metric | EARN | SENS |
|---|---|---|
| Price | $4.43 | $7.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.38 | ★ $18.38 |
| AVG Volume (30 Days) | 417.2K | ★ 622.9K |
| Earning Date | 06-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | $7.69 | $74.15 |
| Revenue Next Year | $19.57 | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $4.25 | $0.41 |
| 52 Week High | $5.89 | $8.75 |
| Indicator | EARN | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 76.38 |
| Support Level | $4.29 | $7.35 |
| Resistance Level | $4.48 | $8.49 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | 0.01 | 0.37 |
| Stochastic Oscillator | 72.00 | 79.62 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.